NASDAQ:SLDB - Solid Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.94 +0.44 (+5.18 %) (As of 02/22/2019 03:49 PM ET)Previous Close$8.50Today's Range$8.53 - $9.1152-Week Range$5.97 - $54.84Volume14,261 shsAverage Volume1.48 million shsMarket Capitalization$316.74 millionP/E Ratio-3.09Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Receive SLDB News and Ratings via Email Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLDB Previous Symbol CUSIPN/A CIK1707502 Webwww.solidbio.com Phone617-337-4680Debt Debt-to-Equity RatioN/A Current Ratio13.96 Quick Ratio13.96Price-To-Earnings Trailing P/E Ratio-3.09 Forward P/E Ratio-4.05 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.73) per share Price / Book-5.17Profitability EPS (Most Recent Fiscal Year)($2.88) Net Income$-52,110,000.00 Net MarginsN/A Return on Equity-63.10% Return on Assets-45.38%Miscellaneous Employees60 Outstanding Shares35,430,000Market Cap$316.74 million Next Earnings Date4/4/2019 (Estimated) OptionableOptionable Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions What is Solid Biosciences' stock symbol? Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB." How were Solid Biosciences' earnings last quarter? Solid Biosciences Inc (NASDAQ:SLDB) posted its earnings results on Tuesday, November, 13th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.01. View Solid Biosciences' Earnings History. When is Solid Biosciences' next earnings date? Solid Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for Solid Biosciences. What price target have analysts set for SLDB? 8 equities research analysts have issued 12-month price targets for Solid Biosciences' shares. Their forecasts range from $8.00 to $57.00. On average, they anticipate Solid Biosciences' stock price to reach $32.6667 in the next twelve months. This suggests a possible upside of 267.0% from the stock's current price. View Analyst Price Targets for Solid Biosciences. What is the consensus analysts' recommendation for Solid Biosciences? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences. What are Wall Street analysts saying about Solid Biosciences stock? Here are some recent quotes from research analysts about Solid Biosciences stock: 1. According to Zacks Investment Research, "Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts. " (2/13/2019) 2. Chardan Capital analysts commented, "We increase our SLDB PT to $60 (from $37.50) on recent reports of efficacy shown for AAV-based gene therapies (GTs) in Duchenne muscular dystrophy (DMD) across several ongoing trials, including Solid’s trial. Our PT increase is also driven by the 18 June announced resolution of the clinical hold on SGT-001. We believe early patient reports (see bullets below) suggest breakthroughs could be in progress for AAV- based gene therapies for DMD being developed by Therapeutics (unrated), and Pfizer (unrated). Positive early data from clinical trials from 3 different companies, to us, supports the utility of microdystrophin GT in a devastating disease with no effective approved therapies. therefore update our Chardan DMD Model (discussed below; see Figure 1), which drives our SLDB PT increase to $60." (6/24/2018) Has Solid Biosciences been receiving favorable news coverage? News coverage about SLDB stock has been trending somewhat positive on Friday, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Solid Biosciences earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. Who are some of Solid Biosciences' key competitors? Some companies that are related to Solid Biosciences include Iovance Biotherapeutics (IOVA), Autolus Therapeutics (AUTL), Audentes Therapeutics (BOLD), Rubius Therapeutics (RUBY), Coherus Biosciences (CHRS), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Vericel (VCEL), BAVARIAN NORDIC/S (BVNRY), Heska (HSKA), Novavax (NVAX), NanoString Technologies (NSTG) and Cellectis (CLLS). What other stocks do shareholders of Solid Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include SUMMIT THERAPEU/S (SMMT), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Portola Pharmaceuticals (PTLA), Verastem (VSTM), Crispr Therapeutics (CRSP) and Ocular Therapeutix (OCUL). Who are Solid Biosciences' key executives? Solid Biosciences' management team includes the folowing people: Dr. Andrey Juan Zarur, Co-Founder & Chairman of DirectorsMr. Ilan Ganot, Co-Founder, CEO, Pres & Director (Age 45)Mr. Matthew Bennett Arnold, Co-Founder & Director (Age 49)Ms. Jennifer Ziolkowski CPA, CFO, Treasurer & Assistant Sec. (Age 45)Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48) When did Solid Biosciences IPO? (SLDB) raised $130 million in an initial public offering on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers. Who are Solid Biosciences' major shareholders? Solid Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Partner Fund Management L.P. (3.77%), BlackRock Inc. (3.43%), Jennison Associates LLC (2.22%), Artal Group S.A. (1.41%), Northern Trust Corp (0.48%) and Geode Capital Management LLC (0.47%). Company insiders that own Solid Biosciences stock include Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Life Sciences Maste Perceptive, Matthew Bennett Arnold and Pedro Alvaro Amorrortu. View Institutional Ownership Trends for Solid Biosciences. Which major investors are selling Solid Biosciences stock? SLDB stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, RTW Investments LP, WS Management Lllp and MetLife Investment Advisors LLC. Company insiders that have sold Solid Biosciences company stock in the last year include Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Matthew Bennett Arnold and Pedro Alvaro Amorrortu. View Insider Buying and Selling for Solid Biosciences. Which major investors are buying Solid Biosciences stock? SLDB stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Partner Fund Management L.P., BlackRock Inc., Artal Group S.A., Citigroup Inc., Geode Capital Management LLC, Bank of New York Mellon Corp and Rhumbline Advisers. View Insider Buying and Selling for Solid Biosciences. How do I buy shares of Solid Biosciences? Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Solid Biosciences' stock price today? One share of SLDB stock can currently be purchased for approximately $8.90. How big of a company is Solid Biosciences? Solid Biosciences has a market capitalization of $315.33 million. The company earns $-52,110,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis. Solid Biosciences employs 60 workers across the globe. What is Solid Biosciences' official website? The official website for Solid Biosciences is http://www.solidbio.com. How can I contact Solid Biosciences? Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680. MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 130 (Vote Outperform)Underperform Votes: 109 (Vote Underperform)Total Votes: 239MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: Options Trading - What is a Straddle?